Sensitive skin types might need to start slower and use it less frequently, while normal to oily skin can typically handle more regular use
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
The points program, with 350+ zero point foods, will not change
Injectable forms generally offer stronger and more predictable results, while nasal sprays provide a simpler and more approachable option for patients prioritizing ease of use
With increased stability, oral preparations also have extended durations of action, further increasing their therapeutic potential [9, 10, 11, 12]
Vitamin B 12 deficiency: case report and review of literature
